The fourth and most important goal is to harmonize all of the above information for the purpose of designing clinical trials using to assess our ability to eliminate harmful bacteria and encourage beneficial bacteria.

 

We envision a clinical trial in which individuals would receive either a protective microbiota substance, or perhaps an antibiotic effective against a culprit bacteria. We expect to start this phase of the work only after a clear picture has emerged on how we should manipulate the microbiota of patients. Realistically, this is likely to be in the third or fourth year, depending on the emerging laboratory results.